Sign up to save your podcastsEmail addressPasswordRegisterOrContinue with GoogleAlready have an account? Log in here.
February 03, 2023The Pros of mRNA Compared with Recombinant Protein Regarding Passive Immunization11 minutesPlayCell-free productionUniform physiochemistry of drug substancesThe same technology for all antibody formatsPotential for storage at ambient temperaturemRNA half-life confers improved pharmacokineticsAccessibility of intracellular targetsPotentially improved tolerability due to patient-specific antibody modificationOpportunity to reduce systemic exposure by in situ synthesisPotential of high antibody titers with low doses of drug substancehttps://mrna.creative-biolabs.com/therapeutic-antibody-coding-mrna.htm...moreShareView all episodesBy Echo HanFebruary 03, 2023The Pros of mRNA Compared with Recombinant Protein Regarding Passive Immunization11 minutesPlayCell-free productionUniform physiochemistry of drug substancesThe same technology for all antibody formatsPotential for storage at ambient temperaturemRNA half-life confers improved pharmacokineticsAccessibility of intracellular targetsPotentially improved tolerability due to patient-specific antibody modificationOpportunity to reduce systemic exposure by in situ synthesisPotential of high antibody titers with low doses of drug substancehttps://mrna.creative-biolabs.com/therapeutic-antibody-coding-mrna.htm...more
Cell-free productionUniform physiochemistry of drug substancesThe same technology for all antibody formatsPotential for storage at ambient temperaturemRNA half-life confers improved pharmacokineticsAccessibility of intracellular targetsPotentially improved tolerability due to patient-specific antibody modificationOpportunity to reduce systemic exposure by in situ synthesisPotential of high antibody titers with low doses of drug substancehttps://mrna.creative-biolabs.com/therapeutic-antibody-coding-mrna.htm
February 03, 2023The Pros of mRNA Compared with Recombinant Protein Regarding Passive Immunization11 minutesPlayCell-free productionUniform physiochemistry of drug substancesThe same technology for all antibody formatsPotential for storage at ambient temperaturemRNA half-life confers improved pharmacokineticsAccessibility of intracellular targetsPotentially improved tolerability due to patient-specific antibody modificationOpportunity to reduce systemic exposure by in situ synthesisPotential of high antibody titers with low doses of drug substancehttps://mrna.creative-biolabs.com/therapeutic-antibody-coding-mrna.htm...more
Cell-free productionUniform physiochemistry of drug substancesThe same technology for all antibody formatsPotential for storage at ambient temperaturemRNA half-life confers improved pharmacokineticsAccessibility of intracellular targetsPotentially improved tolerability due to patient-specific antibody modificationOpportunity to reduce systemic exposure by in situ synthesisPotential of high antibody titers with low doses of drug substancehttps://mrna.creative-biolabs.com/therapeutic-antibody-coding-mrna.htm